Asymptotic properties of mean survival estimate based on the Kaplan-Meier curve with an extrapolated tail

Pharmaceutical Statistics

Volumn 11, Issue 2, 2012, Pages 135-140

  Gong, Qi ^a   Fang, Liang ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b GENENTECH INC   (United States)

Author keywords

extrapolation; mean survival; quality adjusted lifetime; restricted mean survival; variance estimate

Indexed keywords

ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; EXTRAPOLATED TAIL; KAPLAN MEIER METHOD; PROBABILITY; SIMULATION; STATISTICAL DISTRIBUTION; STATISTICAL PARAMETERS; SURVIVAL TIME;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; KAPLAN-MEIER ESTIMATE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 84858450702     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.514     Document Type: Article

References (20)

1. Irwin JO,. The standard error of an estimate of expectational life. Journal of Hygiene 1949; 47: 188-189.
2. Karrison T,. Use of Irwin's restricted mean as an index for comparing survival in different treatment groups-interpretation and power considerations. Controlled Clinical Trials 1997; 18: 151-167. (Pubitemid 27225892)
3. Pepe MS, Fleming TR,. Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. Biometrics 1989; 45: 497-507. (Pubitemid 19165261)
4. Pepe MS, Fleming TR,. Weighted Kaplan-Meier statistics: large sample and optimality considerations. Journal of the Royal Statistical Society, Series B 1991; 53: 341-352.
5. Chen P, Tsiatis AA,. Causal inference on the difference of the restricted mean lifetime between two groups. Biometrics 2001; 57: 1030-1038. (Pubitemid 33108093)
6. Zucker DM,. Restricted mean life with covariates: modification and extension of a useful survival analysis method. Journal of the American Statistical Association 1998; 93: 702-709.
7. Shen Y, Cai J,. Maximum of the weighted Kaplan-Meier tests with application to cancer prevention and screening trials. Biometrics 2001; 57: 837-843. (Pubitemid 32801180)
8. Gelber RD, Cole BF, Gelber S, Goldhirsch A,. Comparing treatment using quality adjusted survival: the Q-TWiST method. American Statistician 1995; 49: 161-169.
9. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS,. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. Journal of Clinical Oncology 1989; 7 (1): 36-44. (Pubitemid 19089079)
10. Efron B,. The two sample problem with censored data. Proceedings of the 5th Berkeley Symposium on Mathematical Statistics and Probability 1967; 4: 831-852.
11. Moeschberger ML, Klein JP,. A comparison of several methods of estimating the survival function when there is extreme right censoring. Biometrics 1985; 41: 253-259.
12. Klein JP, Lee S, Moeschberger ML,. A partially parametric estimator of survival in the presence of randomly censored data. Biometrics 1990; 46: 795-811. (Pubitemid 20333611)
13. Gelber RD, Goldhirsch A, Cole BF,. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. Controlled Clinical Trials 1993; 14: 485-499. (Pubitemid 24003706)
14. Gill RD,. Censoring and stochastic integrals. In Mathematical Centre Tracts, 124. Mathematisch Centrum: Amsterdam, 1980.
15. Gill R,. Large sample behaviour of the product-limit estimator on the whole line. The Annals of Statistics 1983; 11 (1): 49-58.
16. Klein JP, Moeschberger ML,. Survival analysis: techniques for censored and truncated data, 2nd ed. Springer: New York, 2003.
17. Su Z, Fang L,. A novel method to calculate mean survival time for time-to-event data. Communications in Statistics-Simulation and Computation 2011, accepted for publication.
18. Cutsem EV, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon J, Laethem JV, Maurel J, Richardson G, Wolf M, Amado RG,. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 2007; 25: 1658-1664. (Pubitemid 46797944)
19. Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M,. Estimating survival gain for economic evaluations with survival time as principle endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Economics 2002; 11 (3): 233-48. (Pubitemid 34284848)
20. Shen Y, Fleming TR,. Weighted mean survival test statistics: a class of distance tests for censored survival data. Journal of Royal Statistical Society, Series B 1997; 59: 269-280. (Pubitemid 127686953)